NASDAQ · Financial Statements

BioMarin Pharmaceutical Inc. (BMRN) Financial Statements

$55.95 NASDAQ: BMRN Market Cap $10.83B

BioMarin Pharmaceutical Inc. most recently reported annual revenue of $3.2B, net profit of $349.0M. Revenue grew at an average annual rate of 11.6% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

BioMarin Pharmaceutical Inc.: Revenue rose from $1.1B in 2016 to $3.2B in 2025, a change of +188.4% over 9 years; net profit was positive in 5 of 10 reported years; operating margin moved from -71.9% to 16.6%, a shift of +88.5 percentage points; the most recent year shows net profit of $349.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$1.1B$1.3B$1.5B$1.7B$1.9B$1.8B$2.1B$2.4B$2.9B$3.2B
Operating Expenses$1.9B$1.3B$1.6B$1.8B$1.9B$1.9B$1.9B$2.2B$2.4B$2.7B
Operating Profit$-803.0M$-15.0M$-124.0M$-100.0M$-43.0M$-82.0M$161.0M$186.0M$484.0M$533.0M
Operating Margin-71.9%-1.1%-8.3%-5.9%-2.3%-4.5%7.7%7.7%17.0%16.6%
Other Income$-28.0M$-21.0M$-19.0M$6.0M$-6.0M$7.0M$-11.0M$3.0M$58.0M$-51.0M
Interest$39.0M$43.0M$44.0M$23.0M$29.0M$15.0M$16.0M$17.0M$13.0M$11.0M
Depreciation$97.0M$88.0M$96.0M$105.0M$105.0M$108.0M$102.0M$104.0M$96.0M$80.0M
Profit Before Tax$-831.0M$-36.0M$-143.0M$-95.0M$-49.0M$-75.0M$150.0M$189.0M$542.0M$482.0M
Tax$24.2M$-226.3M$45.9M$74.8M$1.8B$15.0M$5.4M$11.1M$21.2M$27.7M
Net Profit$-630.0M$-117.0M$-77.0M$-24.0M$854.0M$-64.0M$142.0M$168.0M$427.0M$349.0M
EPS$-3.79$-0.67$-0.44$-0.13$4.53$-0.35$0.75$0.88$2.21$1.80
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$581.0M$646.0M$649.0M$712.0M$746.0M$747.0M$745.0M$825.0M$776.0M$875.0M$766.0M$990.0M
Operating Expenses$551.0M$632.0M$560.0M$592.0M$632.0M$586.0M$521.0M$549.0M$823.0M$795.0M$637.0M$879.0M
Operating Profit$31.0M$14.0M$88.0M$120.0M$114.0M$161.0M$224.0M$277.0M$-47.0M$79.0M$130.0M$111.0M
Operating Margin5.3%2.2%13.6%16.9%15.3%21.6%30.1%33.5%-6.0%9.1%16.9%11.2%
Interest$4.0M$6.0M$4.0M$4.0M$3.0M$3.0M$3.0M$3.0M$3.0M$3.0M$15.0M$63.0M
Profit Before Tax$42.0M$19.0M$106.0M$132.0M$134.0M$170.0M$238.0M$298.0M$-26.0M$-27.0M$141.0M$61.0M
Tax$3.1M$-5.4M$16.0M$18.9M$21.1M$26.4M$22.0M$19.3M$-16.8M$-71.5M$25.3M$27.1M
Net Profit$40.0M$20.0M$89.0M$107.0M$106.0M$125.0M$186.0M$241.0M$-31.0M$-47.0M$106.0M$45.0M
EPS$0.21$0.11$0.46$0.55$0.55$0.64$0.95$1.23$-0.16$-0.22$0.54$0.23

Over the 10 years reported for BioMarin Pharmaceutical Inc., borrowings decreased from $683.0M in 2016 to $643.0M in 2025, cash stood at $1.3B in the latest year, shareholders' equity was $0, current assets covered current liabilities 5.21 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$4.0B$4.6B$4.4B$4.7B$5.8B$6.0B$6.4B$6.8B$7.0B$7.6B
Current Assets$1.4B$2.2B$2.1B$1.9B$2.3B$2.3B$2.8B$3.0B$3.2B$4.0B
Cash$408.0M$598.0M$494.0M$437.0M$649.0M$587.0M$725.0M$755.0M$943.0M$1.3B
Inventory$355.0M$476.0M$531.0M$680.0M$699.0M$777.0M$894.0M$1.1B$1.2B$1.3B
Receivables$215.0M$261.0M$343.0M$377.0M$448.0M$373.0M$461.0M$634.0M$661.0M$908.0M
Fixed Assets$799.0M$897.0M$949.0M$1.0B$1.0B$1.0B$1.1B$1.1B$1.0B$953.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$954.0M$1.2B$826.0M$728.0M$702.0M$934.0M$901.0M$930.0M$716.0M$747.0M
Other Assets$197.0M$197.0M$197.0M$197.0M$196.0M$196.0M$196.0M$196.0M$196.0M$196.0M
Total Liabilities$1.3B$1.8B$1.5B$1.6B$1.7B$1.7B$1.8B$1.9B$1.3B$1.5B
Current Liabilities$439.0M$817.0M$523.0M$933.0M$493.0M$546.0M$589.0M$1.2B$607.0M$759.0M
Borrowings$683.0M$1.2B$830.0M$859.0M$1.1B$1.1B$1.1B$1.1B$649.0M$643.0M
Other Liabilities$574.0M$650.0M$629.0M$709.0M$655.0M$650.0M$679.0M$794.0M$681.0M$864.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$2.8B$2.8B$3.0B$3.1B$4.1B$4.3B$4.6B$5.0B$5.7B$6.1B

For BioMarin Pharmaceutical Inc., operating cash flow was positive in 8 of 10 reported years; free cash flow in the latest year was $725.0M; free cash flow was positive in 5 of 10 years; financing activities used $57.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$-228.0M$-9.0M$20.0M$48.0M$85.0M$305.0M$176.0M$159.0M$573.0M$828.0M
Investing Cash Flow$-632.0M$-505.0M$120.0M$-176.0M$-191.0M$-486.0M$-141.0M$-219.0M$39.0M$-517.0M
Financing Cash Flow$14.0M$-8.0M$-49.0M$-101.0M$-23.0M$3.0M$-85.0M$-86.0M$-31.0M$-57.0M
Net Cash Flow$11.0M$190.0M$-104.0M$-57.0M$212.0M$-62.0M$137.0M$31.0M$188.0M$369.0M
Free Cash Flow$-376.0M$-208.0M$-124.0M$-97.0M$-52.0M$185.0M$55.0M$52.0M$475.0M$725.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-1.70
EV / EBITDA37.46
FCF Yield6.59%
Quick Ratio1.32
Interest Coverage3.27
Return 1Y1.76%
Return 3Y-37.96%
Return 5Y-27.12%

BioMarin Pharmaceutical Inc. (BMRN) financials — frequently asked questions

What is BioMarin Pharmaceutical Inc.'s annual revenue?

BioMarin Pharmaceutical Inc. (BMRN) reported annual revenue of $3.2B in its most recent fiscal year.

What is BioMarin Pharmaceutical Inc.'s net profit?

BioMarin Pharmaceutical Inc. (BMRN) reported net profit of $349.0M in its most recent fiscal year.

What is BMRN EV/EBITDA?

BioMarin Pharmaceutical Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 37.46.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
BMRN Overview BMRN Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.